Cargando…
Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738052/ https://www.ncbi.nlm.nih.gov/pubmed/31217480 http://dx.doi.org/10.1038/s41416-019-0505-7 |
| _version_ | 1783450772721106944 |
|---|---|
| author | Weisberg, E Manley, P Mestan, J Cowan-Jacob, S Ray, A Griffin, J D |
| author_facet | Weisberg, E Manley, P Mestan, J Cowan-Jacob, S Ray, A Griffin, J D |
| author_sort | Weisberg, E |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6738052 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-67380522020-01-17 Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL Weisberg, E Manley, P Mestan, J Cowan-Jacob, S Ray, A Griffin, J D Br J Cancer Correction Nature Publishing Group UK 2019-06-19 2019-07-30 /pmc/articles/PMC6738052/ /pubmed/31217480 http://dx.doi.org/10.1038/s41416-019-0505-7 Text en © The Author(s), under exclusive licence to Cancer Research UK 2019 https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Correction Weisberg, E Manley, P Mestan, J Cowan-Jacob, S Ray, A Griffin, J D Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL |
| title | Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL |
| title_full | Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL |
| title_fullStr | Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL |
| title_full_unstemmed | Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL |
| title_short | Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL |
| title_sort | correction: amn107 (nilotinib): a novel and selective inhibitor of bcr-abl |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738052/ https://www.ncbi.nlm.nih.gov/pubmed/31217480 http://dx.doi.org/10.1038/s41416-019-0505-7 |
| work_keys_str_mv | AT weisberge correctionamn107nilotinibanovelandselectiveinhibitorofbcrabl AT manleyp correctionamn107nilotinibanovelandselectiveinhibitorofbcrabl AT mestanj correctionamn107nilotinibanovelandselectiveinhibitorofbcrabl AT cowanjacobs correctionamn107nilotinibanovelandselectiveinhibitorofbcrabl AT raya correctionamn107nilotinibanovelandselectiveinhibitorofbcrabl AT griffinjd correctionamn107nilotinibanovelandselectiveinhibitorofbcrabl |